Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2020

Open Access 01.12.2020 | Research

Metastasis to para-aortic lymph nodes cephalad to the renal veins in patients with ovarian cancer

verfasst von: Shinichi Komiyama, Masaru Nagashima, Tomoko Taniguchi, Takayuki Rikitake, Mineto Morita

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2020

Abstract

Background

In patients with epithelial ovarian cancer, whether metastasis to para-aortic lymph nodes located cephalad to the renal veins (supra-renal PAN) should be classified as regional lymph node metastasis or distant metastasis remains controversial. This study was a preliminary retrospective evaluation of the pattern of supra-renal PAN metastasis in patients with epithelial ovarian cancer.

Methods

The subjects were 25 patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who underwent systematic dissection of the para-aortic nodes, including the supra-renal PAN, and pelvic lymph nodes (PLN). Patient factors, perioperative factors, the number of dissected lymph nodes, and pathological lymph node metastasis were investigated.

Results

Supra-renal PAN metastasis was found in 4/25 patients (16.0%). None of the 14 patients with pT1 or pT2 disease had supra-renal PAN metastasis, while 4/11 patients (36.4%) with pT3 or ypT3 disease had such metastases. None of the patients had isolated supra-renal PAN metastasis, while patients with supra-renal PAN metastasis also had multiple metastases to the infra-renal PAN and PLN.

Conclusions

In patients with epithelial ovarian cancer, supra-renal PAN metastases might be considered to be distant rather than regional metastases. Further studies are needed to better define the clinical significance of supra-renal PAN metastasis.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

The para-aortic lymph nodes (PANs) are located around the abdominal aorta and inferior vena cava and are the regional lymph nodes of the intraperitoneal organs. These nodes can be broadly classified into supra-renal PANs located cephalad (superior) to the renal veins and infra-renal PANs located caudad (inferior) to the renal veins, while the infra-renal PANs can be further classified into nodes located between the renal veins and the inferior mesenteric artery and nodes located between the inferior mesenteric artery and the aortic bifurcation [1].
In patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, the clinical implications of supra-renal PAN metastasis are unclear. According to the International Federation of Gynecology and Obstetrics (FIGO) staging classification, the supra-renal PANs are classified as regional lymph nodes, but it is stated that there is controversy regarding whether supra-renal PAN metastasis should be considered as regional lymph node metastasis (stage III) or distant metastasis (stage IV), and this issue should be investigated further in the future [2]. The chief reason why the clinical significance of supra-renal PAN metastasis remains unclear in patients with epithelial ovarian cancer, including primary peritoneal cancer and fallopian tube cancer, is that metastasis to these nodes has received little attention in the past.
It is possible that supra-renal PAN metastases have not been assessed in many previous studies because these nodes lie dorsal to the pancreas and dissection is difficult due to this anatomic location. In addition, the target region for systematic PAN dissection is below the renal veins in patients with ovarian cancer and dissection of the supra-renal PANs is unusual.
However, the supra-renal PANs can be sites of metastasis or recurrence in patients with advanced ovarian cancer. To determine the optimal surgical management for patients with supra-renal PAN involvement, we have tried various approaches to supra-renal PAN dissection, and we have developed a safe method for dissection of the entire PAN region, including the supra-renal PANs (extended PAN dissection). This method involves complete mobilization of the entire small intestine (including the duodenum) and the right hemicolon to expose the inferior vena cava and abdominal aorta below the epiploic foramen on the inferior surface of the liver. Consequently, it is possible to expand the para-aortic region located cephalad to the renal artery, and it is easy to dissect the supra-renal PANs. Our method is a modification of Kocher’s maneuver for duodenal mobilization and has been named Komiyama’s maneuver for dissection of high para-aortic lymph nodes [3].
We performed the present study to evaluate the pattern of supra-renal PAN metastasis and the feasibility of performing extended PAN dissection in patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Materials and methods

Patients

The subjects of this study were patients with an initial diagnosis of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who underwent extended PAN dissection and pelvic lymph node dissection at Toho University Ohashi Medical Center.
The eligibility criteria for our surgical procedure were as follows: (1) preoperative Eastern Cooperative Oncology Group (ECOG) Performance Status of 0–1; (2) adequate major organ function as evaluated by hematology tests, biochemical tests, coagulation tests, chest and abdominal X-ray examination, and electrocardiography; and (3) written informed consent to surgery provided by the patient. Patients who met any of the following criteria were excluded: (1) a history of intestinal obstruction, (2) uncontrolled diabetes or hypertension, (3) deep venous thrombosis, (4) pancreatic disease, (5) a desire to preserve fertility, (6) borderline malignant tumor, and (7) active double cancer.
The chest and abdomen, including the supra-renal PANs, were examined carefully by computed tomography (CT) before surgery. Staging laparotomy was performed in patients with a clinical diagnosis of early cancer, while primary debulking surgery (PDS) was done in patients with a clinical diagnosis of advanced cancer in whom it was considered that primary surgery would achieve an optimal outcome. In addition, interval debulking surgery (IDS) was performed after 3–4 cycles of neoadjuvant chemotherapy (NAC) with taxanes, platinum, and bevacizumab in patients with clinically suspected advanced cancer in whom it was considered that primary surgery would not be optimal.

Surgical procedure

After pelvic lymph node dissection was completed, Komiyama’s maneuver for extended PAN dissection was carried out as follows (Fig. 1).
(1) The ascending colon was displaced from the right paracolic gutter toward the left side. A retroperitoneal incision was made from the ileocecal region in the cephalic direction along the so-called Monk’s white line on the dorsal side of the ascending colon. At this site, Gerota’s fascia, the ascending mesocolon, and the retroperitoneum coalesce to form the so-called fusion fascia, which continues to the mesentery on the right side of the second part of the duodenum and ends superiorly at the epiploic foramen on the inferior surface of the left lobe of the liver. The fusion fascia was incised through the medial side of Gerota’s fascia toward the root of the right renal vein to separate the right kidney from the ascending colon, which was mobilized to expose the region from the anterior surface of the inferior vena cava (IVC) to the left side of the abdominal aorta. The right ovarian vein runs through the fusion fascia and then through the pelvic cavity toward the midpoint of the IVC, and the right ureter also runs through the fusion fascia, allowing both structures to be easily identified by incising the fascia. After identifying the right ovarian vein, it was transected to expose the IVC below the renal vein (Fig. 1a–c).
(2) Kocher’s maneuver was performed for mobilization of the duodenum. The second part of the duodenum was displaced toward the left side and the incision in the fusion fascia, which was at the root of the right renal vein, was extended to the epiploic foramen. Then, connective tissues were stripped from around the duodenum, and it was mobilized to completely expose the IVC below the inferior surface of the left lobe of the liver (Fig. 1d, e).
(3) A retroperitoneal incision was commenced near the bifurcation of the abdominal aorta into the common iliac arteries and was continued along the medial border of the inferior mesenteric vein toward the ligament of Treitz, allowing complete mobilization of the small intestine and the right hemicolon. After mobilization, the small intestine and right hemicolon were placed in an isolation bag and lifted out of the abdominal cavity to clearly expose the whole aortic region from the superior mesenteric artery to the common iliac artery (Fig. 1f–i).
(4) The right and left renal arteries and the left inferior adrenal vein were identified, taking care to avoid damaging these vessels. When the left high para-aortic lymph nodes were dissected, care was also taken to avoid damaging the left adrenal gland, which is embedded in fatty tissue and is difficult to distinguish from a lymph node. The high para-aortic lymph node region contains important lymphatic channels, including the lumbar lymphatic trunk, the intestinal lymphatic trunk, and the chyle cistern. These structures must be managed carefully to prevent damage that could lead to leakage of chyle and occurrence of chylous ascites. Accordingly, both a vessel sealing system and a vascular clip (double ligation) were employed to prevent such events (Fig. 1j–l). While paying attention to these points, the para-aortic lymph nodes were dissected in the following order (Fig. 2):
  • Infra-renal PANs located on the right and ventral sides of the IVC (A before B).
  • Infra-renal PANs located between the IVC and the abdominal aorta and dorsal to these vessels (C before D).
  • Infra-renal PANs located on the left and ventral sides of the aorta (E before F).
  • Supra-renal PANs located between the IVC and the abdominal aorta and ventral to these vessels (G).
  • Supra-renal PANs located on the left and dorsal sides of the aorta (H).
The target region for supra-renal PAN dissection was bounded by the inferior surface of the left lobe of the liver (superiorly), the right border of the IVC (to the right), the medial border of the left adrenal gland (to the left), and the left inferior adrenal vein (inferiorly). Figure 3 shows an intraoperative view after systematic lymph node dissection.
Before the incision was closed, a hyaluronate carboxymethyl cellulose membrane (Seprafilm ®, Sanofi, Paris, France) was placed into the abdominal cavity to prevent postoperative adhesions and drains were inserted into the abdominal cavity. Cefmetazole was administered from the day of surgery until postoperative day 2 to prevent postoperative infection. Low-dose opioid infusion was provided via an epidural catheter until postoperative day 4 for pain management. Subcutaneous administration of enoxaparin sodium (Clexane ®, Sanofi) was started on postoperative day 2 and continued until postoperative day 7 to prevent postoperative deep venous thrombosis or venous thromboembolism.

Study design

This was a single-center retrospective study. The following patient characteristics and perioperative data were obtained from the medical records: the age, primary tumor site, FIGO stage, tumor histology, serum CA-125 level immediately before surgery, presence or absence of supra-renal PAN measuring ≥ 1 cm on CT before initiation of treatment, presence or absence of ascites at laparotomy, timing of surgery (PDS or IDS), curability of surgery and maximum residual tumor diameter, postoperative Union for International Cancer Control (UICC) pTNM classification (the ypTNM classification was used in patients who received NAC), postoperative duration of hospitalization, operating time, intraoperative blood loss, perioperative complications (from the day of surgery to postoperative day 30), number of dissected lymph nodes, number of metastatic lymph nodes, and locations of metastatic lymph nodes. Formalin-fixed, paraffin-embedded sections of the all dissected lymph nodes were made tissue specimens with the largest section and stained with hematoxylin and eosin. All dissected lymph nodes were examined histologically by pathologists, and metastatic nodes were diagnosed pathologically. When the presence of carcinoma in the parenchyma of the lymph node was observed microscopically, it was diagnosed as lymph node metastasis (Fig. 4). Intraoperative and postoperative complications were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [4].
This study was conducted in compliance with the Declaration of Helsinki, and the protocol was approved by the ethical committee of Toho University Ohashi Medical Center (approval number H-17044). Informed consent was waived by the board due to the retrospective design of this study.

Results

From January 2015 to January 2018, 25 patients underwent extended para-aortic lymph node dissection with pelvic lymph node dissection and their characteristics are shown in Table 1. The median number of dissected supra-renal PANs was 5 (range 2–10). In addition, the median number of dissected infra-renal PANs was 21 (range 12–36), and the median number of dissected pelvic lymph nodes (PLNs) was 26 (range 14–55).
Table 1
Patient characteristics
 
N = 25
N
(%)
Age (years)
 
Median
51
Range
31–72
Preoperative serum CA-125 level (U/ml)*
 
Median
79.6
Range
18.9–428.5
ECOG performance status
 
0
16
64
1
9
36
FIGO stage
 
I A
4
16
I C
7
28
II B
2
8
III A
1
4
III C
10
40
IV A
1
4
Primary tumor site
 
Ovary
21
84
Peritoneum
3
12
Fallopian tube
1
4
Histology
 
High-grade serous carcinoma
12
48
Endometrioid carcinoma
5
20
Clear cell carcinoma
7
28
Others**
1
4
Supra-renal PAN enlargement on CT***
 
Yes
2
8
No
23
92
Ascites at laparotomy
 
Yes
11
44
No
14
56
Timing of surgery
 
PDS or staging
15
60
NAC-IDS***
10
40
Operative procedures
 
TH+BSO
25
100
Omentectomy
25
100
Pelvic lymphadenectomy
25
100
Para-aortic lymphadenectomy
25
100
Pelvic peritoneum stripping
10
40
Abdominal peritoneum stripping
11
44
Recto-sigmoidectomy/anastomosis
1
4
Large bowel resection
1
4
Diaphragm stripping/resection
8
32
Splenectomy
1
4
Liver resection
1
4
Small bowel resection
1
4
Residual tumors
 
No macroscopic residual tumor
20
80
Smaller than 1 cm in diameter
5
20
UICC TNM
 
pT1
12
48
pT2
2
8
pT3 or ypT3
11
44
No. of dissected lymph nodes
 PLN
 
Median
26
Range
14–55
Infra-renal PAN
 
Median
21
Range
12–36
Supra-renal PAN
 
Median
5
Range
2–10
Abbreviations: CA-125 cancer antigen 125, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, TH total hysterectomy, BSO bilateral salpingo-oophorectomy, UICC Union for International Cancer Control, PLN pelvic lymph nodes, PAN para-aortic lymph nodes
*Including data obtained just before IDS
**Serous carcinoma + endometrioid carcinoma
***Enlargement of supra-renal PAN was defined as at least one node ≥ 1 cm on CT before the start of treatment
***Debulking surgery was performed after 3–4 cycles of chemotherapy (platinum + taxane + bevacizumab)
Supra-renal PAN metastasis was found in 4 of the 25 patients (16.0%). There was no supra-renal PAN metastasis in the 12 patients who had pT1 disease (tumor confined to ovaries or fallopian tube) or the 2 patients with pT2 disease (tumor involves one or both ovaries or fallopian tubes with pelvic extension). In contrast, 4 of the 11 patients (36.4%) with advanced pT3 or ypT3 cancer (tumor involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes) had supra-renal PAN metastasis. All 4 patients underwent NAC and the histological diagnosis was high-grade serous carcinoma in all of them. Only 1 of the 4 patients showed supra-renal PAN enlargement on CT before the start of treatment. There were no patients with isolated supra-renal PAN metastasis (Table 2).
Table 2
Details of lymph node metastases in the 25 patients
Primary tumor site
Histological diagnosis
Surgery
Stage (TNM)
Supra-renal PAN
Infra-renal PAN
PLN
No. of metastatic lymph nodes
No. of dissected lymph nodes
No. of metastatic lymph nodes
No. of dissected lymph nodes
No. of metastatic lymph nodes
No. of dissected lymph nodes
Ovary
EC
Staging
pT1A N 0 M0
0
8
0
27
0
48
Ovary
EC
Staging
pT1A N0 M0
0
3
0
17
0
24
Ovary
CCC
Staging
pT1A N0 M0
0
4
0
18
0
20
Ovary
CCC
Staging
pT1A N0 M0
0
5
0
16
0
22
Ovary
EC
Staging
pT1C N0 M0
0
4
0
13
0
25
Ovary
EC
Staging
pT1C N0 M0
0
6
0
31
0
32
Ovary
EC
Staging
pT1C N0 M0
0
2
0
21
0
20
Ovary
Others*
Staging
pT1C N0 M0
0
4
0
19
0
21
Ovary
CCC
Staging
pT1C N0 M0
0
5
0
35
0
55
Ovary
CCC
Staging
pT1C N0 M0
0
4
0
32
0
47
Ovary
CCC
Staging
pT1C N0 M0
0
6
0
20
0
33
Ovary
CCC
Staging
pT1A N1 M0
0
4
1
16
1
24
Ovary
CCC
PDS
pT2B N0 M0
0
7
0
28
0
27
Ovary
HGSC
PDS
pT2B N0 M0
0
2
0
17
0
18
Ovary
HGSC
PDS
pT3C N0 M0
0
3
0
26
0
28
Ovary
HGSC
NAC-IDS
ypT3C N0 M0
0
4
0
20
0
22
Ovary
HGSC
NAC-IDS
ypT3C N0 M0
0
3
0
20
0
25
Ovary
HGSC
NAC-IDS
ypT3C N1 M0
2
5
5
19
4
27
Ovary
HGSC
NAC-IDS
ypT3C N1 M0
4
4
16
19
11
23
Ovary
HGSC
NAC-IDS
ypT3C N1 M0
2
4
2
21
3
25
Fallopian tube
HGSC
NAC-IDS
ypT3C N1 M0
0
5
4
26
5
24
Peritoneum
HGSC
NAC-IDS
ypT3C N1 M0
0
5
5
28
6
19
Peritoneum
HGSC
NAC-IDS
ypT3C N1 M0
0
10
11
36
0
30
Peritoneum
HGSC
NAC-IDS
ypT3C N1 M0
4
5
10
15
10
25
Ovary
HGSC
NAC-IDS
ypT3C N1 M1
0
7
0
12
2
14
Abbreviations: EC endometrioid carcinoma, CCC clear cell carcinoma, HGSC high-grade serous carcinoma, Staging staging surgery, PAN para-aortic lymph nodes, PLN pelvic lymph nodes, NAC neoadjuvant chemotherapy, IDS interval debulking surgery
*Serous carcinoma + endometrioid carcinoma
In the 4 patients with supra-renal PAN metastasis, lymph node mapping was performed to evaluate the relation between the locations of the supra-renal and infra-renal PAN metastases and the presence/absence of PLN metastases. It was found that all patients with supra-renal PAN metastasis also had multiple metastases to the infra-renal PANs and PLNs, but there were no correlations between metastases at particular sites (Table 3). In 11 patients with advanced cancer, differences of background factors and perioperative factors were evaluated between the 4 patients who were positive for supra-renal PAN metastasis and the 7 patients who were negative for such metastasis, but no significant differences were found (data not shown).
Table 3
Mapping of metastatic nodes in the four patients with supra-renal PAN metastases
 
Supra-renal PAN*
Infra-renal PAN*
PLN
Upper**
Lower***
Primary tumor site
Histological diagnosis
Stage (TNM)
Metastatic lymph nodes
Metastatic lymph nodes
Metastatic lymph nodes
Metastatic lymph nodes
G (median)
H (left)
B (right)
G (median)
F (left)
A (right)
C (median)
E (left)
Ovary
HGSC
ypT3CN1M0
N
P
N
P
P
N
P
N
P
Ovary
HGSC
ypT3CN1M0
P
P
N
P
P
P
P
P
P
Ovary
HGSC
ypT3CN1M0
P
N
N
P
P
N
N
P
P
Peritoneum
HGSC
ypT3CN1M0
P
P
P
P
P
N
P
P
P
Abbreviations: PAN para-aortic lymph nodes, PLN pelvic lymph nodes, HGSC high-grade serous carcinoma, P positive, N negative
*For the locations of A–H, see Fig. 2
**PANs located inferior to the renal veins and superior to the inferior mesenteric artery
***PANs located inferior to the inferior mesenteric artery and superior to the aortic bifurcation
With regard to the feasibility of performing extended para-aortic lymph node dissection, the median operating time was 6.3 h, the median intraoperative blood loss was 675 g, and the blood transfusion rate was 40%. Hypoalbuminemia and anemia were frequent perioperative complications, with the incidence rate of grade 3 hypoalbuminemia being 8% and that of grade 2 hypoalbuminemia being 64%, while the incidence rates of grade 3 and grade 2 anemia were 4% and 44%, respectively. Lymphatic complications also showed a relatively high frequency, and grade 2 lymphatic complications were seen in 20% of the patients. Grade 2 peripheral sensory neuropathy was observed in 12% of the patients, but this was an adverse event due to NAC that persisted after surgery. Similarly, hypertension and proteinuria were noted as adverse events due to the bevacizumab component of NAC that persisted after surgery (Table 4).
Table 4
Surgical data and grade 2 or more severe perioperative complications from the day of surgery to postoperative day 30
 
N = 25
Duration of hospitalization (days)
 Median
16
 Range
12–22
Total operating time (minutes)
 Median
380
 Range
295–512
Intraoperative blood loss (g)
 Median
675
 Range
320–1220
Complications
Grade 2
Grade 3
≥ Grade 4
N (%)
N (%)
N (%)
 Wound complications (Wound dehiscence)
1 (4)
0
0
 Infectious complications*
2 (8)
0
0
 Gastrointestinal complications (ileus)
1 (4)
0
0
 Urinary complications (incontinence)
1 (4)
0
0
 Lymphatic complications**
5 (20)
0
0
 Pulmonary complications (pleural effusion)
1 (4)
0
0
 Hypoalbuminemia
16 (64)
2 (8)
0
 Anemia
11 (44)
1 (4)
0
 Hypertension
2 (8)
0
0
 Proteinuria
2 (8)
0
0
 Peripheral sensory neuropathy
3 (12)
0
0
 Other complications***
3 (12)
0
0
 Abscess
1 (4)
0
0
 Bleeding complications
0
0
0
 Thromboembolic complications
0
0
0
 Perforation/anastomotic leak
0
0
0
 Blood transfusion
10 (40)
*Urinary tract infection 1, wound infection 1
**Lymphedema 2, lymphocele 1, lymphedema + lymphocele 2
***Chylous ascites 2, alanine aminotransferase (ALT)/aspartate aminotransferase (AST) increased 1

Discussion

This was the first study to evaluate the actual pattern of metastasis to the para-aortic lymph nodes (PANs) located cephalad to the renal veins in patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. A total of 25 patients were investigated, including 11 with advanced cancer, so the data are only preliminary because the number of subjects was small. Our findings suggested that supra-renal PANs might be considered as distant lymph nodes rather than regional lymph nodes because none of the patients with early cancer had supra-renal PAN metastasis, while such metastasis was only observed in some of the patients with advanced cancer, all of whom also had widespread multiple metastases to other nodes.
There have already been many reports about infra-renal PAN metastasis in patients with epithelial ovarian cancer. A systematic review of 14 articles showed that 7.1% of patients with early cancer (T1 or T2) had infra-renal PAN metastasis, with 4.3% having both PAN and PLN metastases [5]. When PDS was performed in patients with T3 cancer, the incidence rate of infra-renal PAN metastasis was reported to be 52–84.7% [69]. In addition, the incidence rate of infra-renal PAN metastasis was reported to be 47.0–78.5% in patients undergoing IDS, suggesting that PAN metastases were still frequent even after NAC [1012]. In the present study, infra-renal PAN metastasis was observed in 1 out of 14 patients with T1 and T2 cancer (7.1%) versus 8 out of 11 patients with T3 cancer (72.7%). Although the number of subjects was small, our patients seemed to be a typical population with ovarian cancer. However, we actively performed NAC at our institution, so a high proportion of the patients with advanced disease underwent IDS. Accordingly, we cannot exclude the possibility that the frequency of supra-renal PAN metastasis may have been different if a larger proportion of patients had received PDS. Therefore, it is necessary to increase the number of PDS patients drastically to investigate the frequency of supra-renal PAN metastasis in the future study.
None of our patients had isolated supra-renal PAN metastasis and none of the patients with a clinical diagnosis of early cancer had supra-renal PAN metastasis. In addition, supra-renal PAN metastasis was observed in 36.4% of the patients with a clinical diagnosis of advanced cancer (i.e., the incidence rate was relatively low), and all of the patients with supra-renal PAN metastasis also had widespread multiple metastases of the PLNs and infra-renal PANs. These results suggest that the supra-renal PANs might be considered to be distant lymph nodes rather than regional lymph nodes.
Regarding the feasibility of our method of extended para-aortic lymph node dissection, the operating time was slightly longer, hypoalbuminemia and anemia were frequent, but there were no serious complications, and the procedure was tolerable. In particular, intestinal obstruction and chylous ascites were concerns in relation to this operation, but such events were mild and had a low frequency. In this study, extended PAN dissection was not compared directly with conventional PAN dissection. However, the frequency of complications (including pulmonary complications, infection, intestinal complications, thromboembolism, lymphatic complications, and blood transfusion) was similar to or lower than the rates of perioperative complications reported after conventional PAN dissection [8, 1113], suggesting that the safety of extended PAN dissection was not inferior to conventional dissection and that dissecting the supra-renal PANs has little negative impact.
Because the current patient population was small, the findings of this study are limited. Accordingly, collection of more data on extended supra-renal PAN dissection in patients with ovarian cancer is required, and further studies should be conducted in a larger population to evaluate the diagnostic significance of supra-renal PAN metastasis. Although there is no doubt about the diagnostic significance of systematic PAN dissection, there have been some negative reports about its therapeutic value [13, 14], suggesting that accumulation of more data is required to allow further discussion of this issue.

Conclusions

The present findings suggested that supra-renal PAN metastasis should be classified as distant rather than regional metastasis in patients with epithelial ovarian cancer. We also confirmed that our method of extended PAN dissection (Komiyama’s maneuver) was safe and tolerable.

Acknowledgements

We thank Dr. Kei Takahashi, Dr. Toshiaki Oharazeki, Dr. Sachi Yokouchi, and Dr. Yasunori Enomoto from the Department of Surgical Pathology at Toho University Ohashi Medical Center for their helpful cooperation.
This study was supported by a JSPS KAKENHI Grant-in-Aid for Scientific Research (C): Grant Number JP18K09302.
This study was conducted in compliance with the Declaration of Helsinki, and the protocol was approved by the ethical committee of Toho University Ohashi Medical Center (approval number H-17044). Informed consent was waived by the board due to the retrospective design of this study.
Not applicable.

Competing interests

SK has received speaker’s honoraria from Chugai Pharmaceutical. The other authors declare that they have no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Committee on Classification of Regional Lymph Nodes of the Japan Society of Clinical Oncology. Classification of regional lymph nodes in Japan. Int J Clin Oncol 2003;8:248-275. Committee on Classification of Regional Lymph Nodes of the Japan Society of Clinical Oncology. Classification of regional lymph nodes in Japan. Int J Clin Oncol 2003;8:248-275.
2.
Zurück zum Zitat Prat J ; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5. Prat J ; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5.
3.
Zurück zum Zitat Komiyama S, Manrai M, Takahashi R, et al. Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the “Komiyama’s maneuver”, a modification of Kocher’s maneuver. Gynecol Oncol. 2017;145:407–8.CrossRef Komiyama S, Manrai M, Takahashi R, et al. Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the “Komiyama’s maneuver”, a modification of Kocher’s maneuver. Gynecol Oncol. 2017;145:407–8.CrossRef
5.
Zurück zum Zitat Kleppe M, Wang T, Van Gorp T, et al. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123:610–4.CrossRef Kleppe M, Wang T, Van Gorp T, et al. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123:610–4.CrossRef
6.
Zurück zum Zitat du Bois A, Reuss A, Harter P, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom; Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–9.CrossRef du Bois A, Reuss A, Harter P, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom; Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–9.CrossRef
7.
Zurück zum Zitat Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238–44.CrossRef Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238–44.CrossRef
8.
Zurück zum Zitat Gasimli K, Braicu EI, Nassir M, et al. Lymph node involvement pattern and survival differences of FIGO IIIC and FIGO IIIA1 ovarian cancer patients after primary complete tumor debulking surgery: a 10-year retrospective analysis of the Tumor Bank Ovarian Cancer Network. Ann Surg Oncol. 2016;23:1279–86.CrossRef Gasimli K, Braicu EI, Nassir M, et al. Lymph node involvement pattern and survival differences of FIGO IIIC and FIGO IIIA1 ovarian cancer patients after primary complete tumor debulking surgery: a 10-year retrospective analysis of the Tumor Bank Ovarian Cancer Network. Ann Surg Oncol. 2016;23:1279–86.CrossRef
9.
Zurück zum Zitat Ayhan A, Ozkan NT, Sarı ME, et al. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study. J Gynecol Oncol. 2018;29:e12.CrossRef Ayhan A, Ozkan NT, Sarı ME, et al. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study. J Gynecol Oncol. 2018;29:e12.CrossRef
10.
Zurück zum Zitat Fournier M, Stoeckle E, Guyon F, et al. Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients. Int J Gynecol Cancer. 2009;19:1307–13.CrossRef Fournier M, Stoeckle E, Guyon F, et al. Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients. Int J Gynecol Cancer. 2009;19:1307–13.CrossRef
11.
Zurück zum Zitat Fagotti A, De Iaco P, Fanfani F, et al. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study. Ann Surg Oncol. 2012;19:3522–7.CrossRef Fagotti A, De Iaco P, Fanfani F, et al. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study. Ann Surg Oncol. 2012;19:3522–7.CrossRef
12.
Zurück zum Zitat Eoh KJ, Yoon JW, Lee I, et al. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. J Surg Oncol. 2017;116:329–36.CrossRef Eoh KJ, Yoon JW, Lee I, et al. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. J Surg Oncol. 2017;116:329–36.CrossRef
13.
Zurück zum Zitat Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560–6.CrossRef Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560–6.CrossRef
14.
Zurück zum Zitat Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380:822–32.CrossRef Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380:822–32.CrossRef
Metadaten
Titel
Metastasis to para-aortic lymph nodes cephalad to the renal veins in patients with ovarian cancer
verfasst von
Shinichi Komiyama
Masaru Nagashima
Tomoko Taniguchi
Takayuki Rikitake
Mineto Morita
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2020
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-020-01841-8

Weitere Artikel der Ausgabe 1/2020

World Journal of Surgical Oncology 1/2020 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.